未登录

A

Ashraf A. Tabll

Tanta University

H指数:22

被引数:1,428

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A virus-like-particle-producing DNA vaccine triggers specific humoral immunity against hepatitis C virus in mice

一种病毒样颗粒产生DNA疫苗在 mice 中触发针对 hepatitis C virus 的特异性体液免疫

ARCHIVES OF VIROLOGY

IF2.5

2025-11-100

PRE

Insights into antiviral activity of chlorpromazine against RNA viruses: Molecular docking, ADME profile, and semi-in vivo study

氯丙嗪抗RNA病毒活性的研究：分子对接、ADME特征及半体内研究

JOURNAL OF VIROLOGICAL METHODS

IF1.6

2025-11-010

PRE

Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt

BMC BIOTECHNOLOGY

IF3.4

2025-01-180

OAAI

Glycylglycine promotes the solubility and antigenic utility of recombinant HCV structural proteins in a point-of-care immunoassay for detection of active viremia (vol 23, 25, 2024)

MICROBIAL CELL FACTORIES

IF4.9

2024-12-230

OA

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals (vol 21, 293, 2024)

VIROLOGY JOURNAL

IF3.8

2024-12-120

OAAI

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals

VIROLOGY JOURNAL

IF3.8

2024-11-151

OAAI

Glycylglycine promotes the solubility and antigenic utility of recombinant HCV structural proteins in a point-of-care immunoassay for detection of active viremia

MICROBIAL CELL FACTORIES

IF4.9

2024-01-181

OA

Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine

IF3.3

2023-12-313

OAAI

Biomarkers for Hepatocellular Carcinoma: From Origin to Clinical Diagnosis

IF3.9

2023-06-2823

OAAI

Noninvasive Fibrosis Assessment in Chronic Hepatitis C Infection: An Update

clinical and translational gastroenterology

IF4.2

2023-05-113

OAAI

Mechanistic-Based Classification of Endocytosis-Related Inhibitors: Does It Aid in Assigning Drugs against SARS-CoV-2?

IF3.5

2023-04-239

OAAI

Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review

IF3.5

2023-01-1220

OAAI

Therapeutic Perspectives of IL1 Family Members in Liver Diseases: An Update

clinical and translational gastroenterology

IF4.2

2022-08-156

OAAI

Editorial: Importance of cytokines and receptor members from the IL-1 family in the context of chronic autoimmune inflammatory diseases

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-07-192

OAAI

Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection

PHARMACEUTICALS

IF4.8

2021-05-2613

OAAI

An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents

新兴抗肝纤维化药物的疗效和安全性更新

clinical and translational gastroenterology

IF4.2

2021-01-0412

OAAI

Therapeutic potential of a novel combination of Curcumin with Sulfamethoxazole against carbon tetrachloride-induced acute liver injury in Swiss albino mice

JOURNAL OF GENETIC ENGINEERING AND BIOTECHNOLOGY

IF2.8

2020-12-0110

OAAI

Anti-S1 MERS-COV IgY Specific Antibodies Decreases Lung Inflammation and Viral Antigen Positive Cells in the Human Transgenic Mouse Model

IF3.4

2020-11-0113

OAAI

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals

IF3.9

2020-06-2513

OAAI

A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma

ANNALS OF HEPATOLOGY

IF4.4

2020-03-0121

OAAI